Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has a higher price-to-earnings ratio of 40.02x compared to its average ratio, The 36-month beta value for CPRX is at 0.76. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CPRX is 102.43M, and currently, shorts hold a 5.64% of that float. The average trading volume for CPRX on September 20, 2024 was 1.10M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CPRX) stock’s latest price update
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX)’s stock price has increased by 4.50 compared to its previous closing price of 20.43. However, the company has seen a 5.22% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-12 that Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
CPRX’s Market Performance
Catalyst Pharmaceuticals Inc (CPRX) has seen a 5.22% rise in stock performance for the week, with a 3.19% gain in the past month and a 40.65% surge in the past quarter. The volatility ratio for the week is 2.97%, and the volatility levels for the past 30 days are at 2.99% for CPRX. The simple moving average for the past 20 days is 6.08% for CPRX’s stock, with a 32.41% simple moving average for the past 200 days.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Citigroup repeating the rating for CPRX by listing it as a “Buy.” The predicted price for CPRX in the upcoming period, according to Citigroup is $27 based on the research report published on March 14, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $23. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to CPRX, setting the target price at $30 in the report published on December 21st of the previous year.
CPRX Trading at 14.69% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 2.30% of gains for the given period.
Volatility was left at 2.99%, however, over the last 30 days, the volatility rate increased by 2.97%, as shares surge +4.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.10% upper at present.
During the last 5 trading sessions, CPRX rose by +5.22%, which changed the moving average for the period of 200-days by +44.06% in comparison to the 20-day moving average, which settled at $20.17. In addition, Catalyst Pharmaceuticals Inc saw 27.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Tierney David S, who sale 15,000 shares at the price of $20.10 back on Aug 21 ’24. After this action, Tierney David S now owns 348,874 shares of Catalyst Pharmaceuticals Inc, valued at $301,455 using the latest closing price.
Miller Steve, the Chief Op. & Scientific Officer of Catalyst Pharmaceuticals Inc, sale 150,000 shares at $20.35 during a trade that took place back on Aug 20 ’24, which means that Miller Steve is holding 675,124 shares at $3,052,900 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.82 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.16. The total capital return value is set at 0.14. Equity return is now at value 13.85, with 11.85 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 58.3. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 50.4.
Currently, EBITDA for the company is 119.95 million with net debt to EBITDA at -3.04. When we switch over and look at the enterprise to sales, we see a ratio of 4.98. The receivables turnover for the company is 7.6for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.14.
Conclusion
In conclusion, Catalyst Pharmaceuticals Inc (CPRX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
